According to AI News, on September 25th, Tianjing Biotechnology announced that it has reached a strategic cooperation with Sanofi for the development, production, and commercialization of its independently developed global innovative CD73 antibody, Yulelimab, in Greater China. Sanofi will make a down payment of approximately 32 million euros and recent milestone payments to Tianjing Biotechnology, as well as specific registration and sales milestone payments; The maximum potential total consideration shall not exceed 213 million euros.